Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis
C Starvaggi Cucuzza, E Longinetti… - Neurology …, 2022 - AAN Enterprises
Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
E Longinetti, N Ruffin, B Evertsson… - Neurology (r) …, 2022 - europepmc.org
Methods We conducted a prospective observational study in a specialized-care, single-
center setting, including patients with RRMS participating in the COMBAT-MS and …
center setting, including patients with RRMS participating in the COMBAT-MS and …
[PDF][PDF] Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
2022 - researchgate.net
Methods We conducted a prospective observational study in a specialized-care, single-
center setting, including patients with RRMS participating in the COMBAT-MS and …
center setting, including patients with RRMS participating in the COMBAT-MS and …
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
CS Cucuzza, E Longinetti, N Ruffin… - Neurology (R) …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and objectives B cell-depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
[HTML][HTML] Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
C Starvaggi Cucuzza, E Longinetti… - Neurology …, 2023 - AAN Enterprises
Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
[HTML][HTML] Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
CS Cucuzza, E Longinetti, N Ruffin… - Neurology® …, 2023 - ncbi.nlm.nih.gov
Methods We conducted a prospective observational study in a specialized-care, single-
center setting, including patients with RRMS participating in the COMBAT-MS and …
center setting, including patients with RRMS participating in the COMBAT-MS and …
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
E Longinetti, N Ruffin, B Evertsson… - Neurology (r) …, 2022 - europepmc.org
Methods We conducted a prospective observational study in a specialized-care, single-
center setting, including patients with RRMS participating in the COMBAT-MS and …
center setting, including patients with RRMS participating in the COMBAT-MS and …